Summary
IMMOKES is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €154,045 and a net result of €31,621. Equity is growing by about 14% per year across the filed financial years. Its solvency ranks better than 47% of 9,727 sector peers (NACE 64, financial year 2025). The company has been active since 2013 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
29-06
NBB filing
Annual accounts filed
financial year 2025 · micro format
25-03
Gazette deed
Resignation: Benedicte Ameloot (director)Permanent representative: Roel Kestelyn · Director discharge · Registered-office move6 facts ▸
Gazette deed
Resignation: Benedicte Ameloot (director)
Permanent representative: Roel Kestelyn · Director discharge · Registered-office move6 facts ▸
- General meeting, 19-12-2025
- Director resignation, Benedicte Ameloot (director (not named in the articles))
- Director discharge, Benedicte Ameloot
- Registered-office move, Haiglaan 166, 8900 leper
- Power of attorney, BV ACCOFISC
- Permanent representative, Roel Kestelyn
2025
31-12
Financial
Highest result from 2018 to 2025net €31,621 ▲106%
Operating result €37,686, net result €31,621, both a record.
31-12
Financial
Liquidity more than doubledcurrent ratio 2.09
Current ratio from 0.75 to 2.09; short-term debt falls from €56,095 to €21,484.
31-12
Financial
Equity above €150,000equity €154,045 ▲25.8%
7 profitable years in a row build equity to €154,045.
07-08
NBB filing
Annual accounts filed
financial year 2024 · micro format · 7 days late
2024
30-07
NBB filing
Annual accounts filed
financial year 2023 · micro format
2023
31-12
Financial
Equity above €100,000equity €107,062 ▲8.3%
5 profitable years in a row build equity to €107,062.
21-11
Gazette deed
Reappointments: Bénédicte AMELOOT (director) and PHARMAKES (director)Permanent representative: Roel KESTELYN · Purpose change · Amendment of the articles11 facts ▸
Gazette deed
Reappointments: Bénédicte AMELOOT (director) and PHARMAKES (director)
Permanent representative: Roel KESTELYN · Purpose change · Amendment of the articles11 facts ▸
- General meeting, 13-11-2023
- Other provision, “agenda buitengewone algemene vergadering, aanpassing statuten aan Wetboek van vennootschappen en verenigingen met behoud BV en opheffing onbeschikbaarheid statu…” (deed in Dutch)
- Other provision, “aanpassing statuten aan WVV met behoud rechtsvorm en opheffing onbeschikbaarheid, onmiddellijke en integrale opheffing onbeschikbaarheid” (deed in Dutch)
- Purpose change
- Amendment of the articles
- Director reappointment, Bénédicte AMELOOT (director)
- Director reappointment, PHARMAKES (director)
- Permanent representative, Roel KESTELYN
- Registered office clause, “Vlaams Gewest, 8670 Koksijde (Oostduinkerke), Dewittelaan 11 bus 502” (deed in Dutch)
- Power of attorney, Accofisc BV
- Power of attorney
13-07
NBB filing
Annual accounts filed
financial year 2022 · micro format
2022
30-09
NBB filing
Annual accounts filed
financial year 2021 · micro format · 61 days late
2021
29-06
NBB filing
Annual accounts filed
financial year 2020 · micro format
Show earlier events
2020
15-09
NBB filing
Annual accounts filed
financial year 2019 · micro format · 46 days late
2019
31-12
Financial
Back to profitnet €13,409
Net result €13,409 after one loss-making year.
03-07
NBB filing
Annual accounts filed
financial year 2018 · micro format
2018
31-08
NBB filing
Annual accounts filed
financial year 2017 · micro format · 31 days late
2017
09-10
NBB filing
Annual accounts filed
financial year 2016 · micro format · 70 days late
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 12 annual accounts filed, the latest 10 are here; all 12 are under Financials.
2 of 4 deeds read
About the unread acts
Of the 4 Belgian Official Gazette deeds we know for this company, 2 have been read. The other 2 have not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.